Abstract:Selective RET inhibitors has been approved for RET fusion non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy. However, whether RET fusion NSCLC could benefit from immune checkpoint inhibitors (ICIs) remain unclear. This study retrospectively analyzed clinical outcomes of ICIs and RET inhibitors in RET fusion advanced NSCLC. Patients with advanced NSCLC harboring RET fusion who received treatment between January 2017 and September 2021 were analyzed. Data were evaluated for clinicopathologic characteristics and outcomes for ICIs therapy and RET inhibitors. A total of 75 patients were identified with RET fusion advanced NSCLC in our cohort. Median age was 57 years and half of the patients were female (49.3%), most patients were never or light smoking (72%). 17 patients (22.7%) had intracranial metastases and 27 patients (36%) were diagnosed with pleural metastasis. KIF5B-RET accounted for 73.3% (55/75), 12 (16%) patients had CCDC6-RET, three (4%) patients had NCOA4-RET fusion. TP53 ranked as the most common concurrent alteration, and two patients were identified RET fusion after EGFR-TKI resistance. One patient with PD-L1 tumor proportion score 90% responded to first-line pembrolizumab with progression-free survival (PFS) of 5.5 months. 15 patients were given ICIs combined with chemotherapy, most as second-line therapy, five patients (33.3%) achieved an objective response, with median PFS of 6·6 months (95% CI 4.7–8·4). 15 patients received selective RET inhibitors (pralsetinib, selpercatinib). The overall response rate was 53.3% (8/15) and median PFS 10.0 months (95% CI 5.2–14.9). Six patients were given cabozantinib, only one patient obtained response, median PFS was 3.1 months (95% CI 0.9–5.2). One patient acquiring RET fusion after EGFR-TKI resistance received pralsetinib monotherapy and obtained clinic response, PFS has not arrived. Selective RET inhibitors showed durable efficacy compared with cabozantinib for RET fusion NSCLC. ICIs especially for PD-L high and combined strategies may offer comparable benefit for RET fusion NSCLC, warranting further investigation.

Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges

47P Real-world Outcomes of Immune Checkpoint Inhibitors and Selective RET Inhibitors for RET Fusion Non-Small Cell Lung Cancer

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].

Immune Checkpoint Inhibitors in Non-Small-cell Lung Cancer: Current Status and Future Directions

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs"

Efficacy of ICIs on Patients with Oncogene-Driven Non-Small Cell Lung Cancer: a Retrospective Study

Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

Recent Advances and Challenges of Immune Checkpoint Inhibitors in Immunotherapy of Non-Small Cell Lung Cancer

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress